Mosunetuzumab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 149 publications

Odronextamab: a bispecific antibody for follicular lymphoma.

Odronextamab: a bispecific antibody for follicular lymphoma.

Journal: Expert opinion on investigational drugs

Published: June 13, 2026

Odronextamab: a bispecific antibody for follicular lymphoma.

Odronextamab: a bispecific antibody for follicular lymphoma.

Journal: Expert opinion on investigational drugs

Published: June 13, 2026

Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review.

Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: May 24, 2026

Mosunetuzumab Successfully Treated Rituximab-Refractory Lymphoma-Associated Protein-Losing Enteropathy With Concomitant Immune Thrombocytopenia in Follicular Lymphoma: A Case Report.

Mosunetuzumab Successfully Treated Rituximab-Refractory Lymphoma-Associated Protein-Losing Enteropathy With Concomitant Immune Thrombocytopenia in Follicular Lymphoma: A Case Report.

Journal: EJHaem

Published: April 24, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

Journal: International journal of clinical oncology

Published: April 09, 2026

New Diagnosis of B-cell Follicular Lymphoma Temporally Associated With Routine Vaccination: A Report of Two Cases.

New Diagnosis of B-cell Follicular Lymphoma Temporally Associated With Routine Vaccination: A Report of Two Cases.

Journal: Cureus

Published: April 07, 2026

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.

Journal: Blood neoplasia

Published: March 20, 2026

Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas.

Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas.

Journal: Journal of hematology & oncology

Published: March 09, 2026

Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus.

Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus.

Journal: Lupus science & medicine

Published: February 18, 2026

Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

Journal: The oncologist

Published: February 18, 2026

Real-world safety profile of mosunetuzumab: a pharmacovigilance study based on the food and drug administration adverse event reporting system.

Real-world safety profile of mosunetuzumab: a pharmacovigilance study based on the food and drug administration adverse event reporting system.

Journal: Frontiers in pharmacology

Published: February 12, 2026

Safety and Efficacy of Mosunetuzumab: Experience in the Hospital Cardinale Giovanni Panico.

Safety and Efficacy of Mosunetuzumab: Experience in the Hospital Cardinale Giovanni Panico.

Journal: Antibodies (Basel, Switzerland)

Published: February 10, 2026

Showing 1-12 of 149

Last Updated: 06/30/2026